A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Clinical trial NCT05578092 · TERMINATED

Trial details

NCT number: NCT05578092
Sponsor: Mirati Therapeutics Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor Advanced Solid Tumor Non Small Cell Lung Cancer Colo-rectal Cancer

Start date: 2022-12-02
Primary completion: 2026-02-03
Enrollment: 64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.